May 29, 2018
Bioanalysis Rising Star Award 2018 finalists announced
Bioanalysis Zone has announced the three finalists of the 2018 Bioanalysis Rising Star Award (BRSA) following careful consideration by a panel of expert judges.
After launching nominations for the BRSA earlier this year, Bioanalysis Zone has been overwhelmed with the community’s enthusiasm to recognize and promote the work of early career scientists in the bioanalytical community.
Now in its 8th year, the BRSA has had a record-breaking year for nominations with the standard of all the candidates being incredibly high. The Zone would like to thank all nominees and those who nominated.
After much deliberation by the judges and with the support of the Award’s sponsor, Waters Corporation (MA, USA), Bioanalysis Zone is delighted to announce the finalists for this year’s BRSA:
The winner of the 2018 BRSA will be decided by the bioanalysis community by public vote: voting is now open and can be found on Bioanalysis Zone. In addition, a video from each of the finalists can be found on the Zone, featuring a short interview in which each finalist shares their research and the reasons why they should be this year’s winner.
For any enquiries email Naamah Maundrell, Senior Editor of Bioanalysis Zone, at firstname.lastname@example.org
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 9,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, peer-reviewed research, exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.